Literature DB >> 35611129

Personalized Medicine: Yesterday, Today, and Tomorrow.

.   

Abstract

Entities:  

Year:  2021        PMID: 35611129      PMCID: PMC9122057     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN: 1554-7914


× No keyword cloud information.
  7 in total

1.  A validated web-based tool to display individualised Crohn's disease predicted outcomes based on clinical, serologic and genetic variables.

Authors:  C A Siegel; H Horton; L S Siegel; K D Thompson; T Mackenzie; S K Stewart; P W Rice; J M Stempak; S Dezfoli; T Haritunians; A Levy; M Baek; R Milgrom; P S Dulai; S R Targan; M S Silverberg; M C Dubinsky; D P McGovern
Journal:  Aliment Pharmacol Ther       Date:  2015-11-15       Impact factor: 8.171

2.  Clinical and biological predictors of response to standardised paediatric colitis therapy (PROTECT): a multicentre inception cohort study.

Authors:  Jeffrey S Hyams; Sonia Davis Thomas; Nathan Gotman; Yael Haberman; Rebekah Karns; Melanie Schirmer; Angela Mo; David R Mack; Brendan Boyle; Anne M Griffiths; Neal S LeLeiko; Cary G Sauer; David J Keljo; James Markowitz; Susan S Baker; Joel Rosh; Robert N Baldassano; Ashish Patel; Marian Pfefferkorn; Anthony Otley; Melvin Heyman; Joshua Noe; Maria Oliva-Hemker; Paul A Rufo; Jennifer Strople; David Ziring; Stephen L Guthery; Boris Sudel; Keith Benkov; Prateek Wali; Dedrick Moulton; Jonathan Evans; Michael D Kappelman; M Alison Marquis; Francisco A Sylvester; Margaret H Collins; Suresh Venkateswaran; Marla Dubinsky; Vin Tangpricha; Krista L Spada; Bradley Saul; Jessie Wang; Jose Serrano; Kevin Hommel; Urko M Marigorta; Greg Gibson; Ramnik J Xavier; Subra Kugathasan; Thomas Walters; Lee A Denson
Journal:  Lancet       Date:  2019-03-29       Impact factor: 79.321

3.  What is the role of serological markers in the diagnosis of IBD?

Authors:  Marla C Dubinsky
Journal:  Inflamm Bowel Dis       Date:  2008-10       Impact factor: 5.325

4.  Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease.

Authors:  Nathaniel R West; Ahmed N Hegazy; Benjamin M J Owens; Samuel J Bullers; Bryan Linggi; Sofia Buonocore; Margherita Coccia; Dieter Görtz; Sébastien This; Krista Stockenhuber; Johanna Pott; Matthias Friedrich; Grigory Ryzhakov; Frédéric Baribaud; Carrie Brodmerkel; Constanze Cieluch; Nahid Rahman; Gerhard Müller-Newen; Raymond J Owens; Anja A Kühl; Kevin J Maloy; Scott E Plevy; Satish Keshav; Simon P L Travis; Fiona Powrie
Journal:  Nat Med       Date:  2017-04-03       Impact factor: 53.440

5.  Effects of Anti-Integrin Treatment With Vedolizumab on Immune Pathways and Cytokines in Inflammatory Bowel Diseases.

Authors:  Timo Rath; Ulrike Billmeier; Fulvia Ferrazzi; Michael Vieth; Arif Ekici; Markus F Neurath; Raja Atreya
Journal:  Front Immunol       Date:  2018-07-31       Impact factor: 7.561

6.  Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations.

Authors:  Amit V Khera; Mark Chaffin; Krishna G Aragam; Mary E Haas; Carolina Roselli; Seung Hoan Choi; Pradeep Natarajan; Eric S Lander; Steven A Lubitz; Patrick T Ellinor; Sekar Kathiresan
Journal:  Nat Genet       Date:  2018-08-13       Impact factor: 38.330

7.  Low TREM1 expression in whole blood predicts anti-TNF response in inflammatory bowel disease.

Authors:  Bram Verstockt; Sare Verstockt; Jonas Dehairs; Vera Ballet; Helene Blevi; Willem-Jan Wollants; Christine Breynaert; Gert Van Assche; Séverine Vermeire; Marc Ferrante
Journal:  EBioMedicine       Date:  2019-01-24       Impact factor: 8.143

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.